An exclusive “Ask the Expert” Q&A session with the esteemed medical oncologist from Memorial Sloan Kettering Cancer Center, Dr. Tiffany Traina, a luminary in the field of oncology, particularly in the battle against TNBC.

**Summary of the transcript below**

As the landscape of cancer treatment rapidly advances, one of the most exciting innovations on the horizon is the development of antibody-drug conjugates (ADCs). These treatments represent a promising shift towards targeted therapy that maximizes effectiveness while minimizing harm to healthy cells. ADCs are specifically designed antibodies that target cancer cells directly, delivering high concentrations of chemotherapy precisely to cancer cells. This targeted approach reduces the widespread side effects often associated with traditional intravenous chemotherapy.

ADCs have already made significant strides, particularly in treating triple-negative breast cancer (TNBC). Recently FDA-approved ADCs, such as sacituzumab govitecan (Trodelvy) and trastuzumab deruxtecan (Enhertu), have shown improved survival rates for patients and are poised to become foundational therapies in breast cancer treatment.

Research is expanding the use of ADCs beyond metastatic cancer, exploring their potential in treating high-risk, early-stage cancers. This could enhance cure rates and improve long-term outcomes for patients with aggressive forms of cancer. Additionally, new drugs in the ADC category, such as datopotamab deruxtecan (DAT-DXd), are undergoing clinical trials, showing promise in earlier-stage cancers and in combination with immunotherapies.

As the understanding of cancer mutations deepens, the future of breast cancer treatment looks increasingly bright, with ADCs and other targeted therapies promising a more personalized, effective approach to cancer care.